CTKB
Cytek Biosciences, Inc.
CTKB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CTKB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
CTKB's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CTKB PE Valuation
CTKB has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CTKB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
CTKB has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CTKB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.54 |
| Q2 2026 | -$0.63 | -$0.58 |
| Q1 2026 | -$0.58 | -$0.49 |
| Q4 2025 | -$0.52 | -$0.47 |
| Q3 2025 | -$0.10 | -$0.02 |
| Q2 2025 | -$0.05 | +$0.09 |
| Q1 2025 | -$0.09 | $0.00 |
| Q4 2024 | -$0.05 | +$0.04 |
CTKB lost $0.64 per share over the past year, and its loss has widened in each of the last five quarters.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over CTKB on earnings, with more consistent year-over-year improvement.
CTKB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.2M | +1.8% |
| Q2 2026 | $48.1M | +5.6% |
| Q1 2026 | $44.1M | +6.5% |
| Q4 2025 | $62.1M | +8.1% |
| Q3 2025 | $52.3M | +1.5% |
| Q2 2025 | $45.6M | -2.2% |
| Q1 2025 | $41.5M | -7.6% |
| Q4 2024 | $57.5M | -1.3% |
CTKB's revenue has grown year over year for five quarters in a row: $53M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -16% | +1.8 points |
| Q2 2026 | -24% | -0.4 points |
| Q1 2026 | -42% | -5.7 points |
| Q4 2025 | -9% | -14 points |
| Q3 2025 | -18% | -9.3 points |
| Q2 2025 | -23% | -5 points |
| Q1 2025 | -36% | -12 points |
| Q4 2024 | 5.2% | +5.4 points |
CTKB's operating margin was −16% last quarter, up 1.8 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CTKB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CTKB on profitability, with a higher operating margin.
CTKB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6M | -$1.4M |
| Q2 2026 | -$849K | +$620K |
| Q1 2026 | -$4.9M | -$3.9M |
| Q4 2025 | -$1.8M | -261% |
| Q3 2025 | -$4.6M | -137% |
| Q2 2025 | -$1.5M | -129% |
| Q1 2025 | -$974K | -129% |
| Q4 2024 | $1.1M | -86% |
CTKB has burned cash in seven of the last eight quarters: −$13M over the past year, against −$6M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CTKB on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTKB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +898K shares |
| 1 year | +2.2% | +2.8M shares |
| 3 years | -4.3% | -5.8M shares |
| 5 years | +260% | +94.2M shares |
| Available history | +6% | +7.3M shares |
CTKB has 130M diluted shares, up 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $34,000 |
| Q3 2025 | $29,000 |
| Q2 2025 | $4.5M |
| Q1 2025 | $10.6M |
| Q4 2024 | $7M |
CTKB has spent almost nothing on buybacks in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CTKB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CTKB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -431.1x | Net Cash |
| Q3 2022 | -185.1x | Net Cash |
| Q2 2022 | -100.0x | Net Cash |
| Q1 2022 | -48.1x | Net Cash |
| Q4 2021 | -37.2x | Net Cash |
| Q3 2021 | -23.1x | Net Cash |
| Q2 2021 | -7.9x | Net Cash |
| Q1 2021 | -10.0x | Net Cash |
CTKB has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CTKB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.6 | Neutral |
| Stochastic | 77.2 | Neutral |
CTKB's weekly RSI is 57 (neutral) and its Stochastic is 77 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CTKB PE vs Healthcare Sector
| Metric | CTKB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTKB has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CTKB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.66 | 2.5% below |
| 20 week MA | $5.04 | 9.5% above |
| 50 week MA | $4.73 | 17% above |
| 100 week MA | $4.50 | 23% above |
| 200 week MA | $5.95 | 7.2% below |
CTKB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CTKB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.8 | $17.3 | -8% |
| 2022 | $17.3 | $10.1 | -41% |
| 2023 | $10.1 | $9.12 | -9.9% |
| 2024 | $9.12 | $6.39 | -30% |
| 2025 | $6.39 | $5.10 | -20% |
| 2026 YTD | $5.10 | $5.52 | +8.2% |
CTKB has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.